Sex differences in tau may help explain why women face higher Alzheimer's dementia risk than men. At high levels of brain ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

The brain of a US woman with Down syndrome showed the classic signs of Alzheimer’s disease upon her death, yet she remained ...

Reducing seven risk factors for heart disease and having higher Life's Simple 7 scores may help decrease biomarkers for ...

The choice to have children can be fraught with medical, financial and ethical hurdles, with the public health system ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $341.93, with a high estimate of $500.00 and a low estimate of $280.00. Marking an increase ...

Explore the spectrum of dementia, its causes, and how it impacts cognitive health, with insights into care strategies and prevention methods.

Asceneuron is the latest biotech to face setbacks in developing tau-targeting therapies for Alzheimer’s. After Eli Lilly and ...

New UK study reveals daily physical activity reduces brain disease risk from dementia to depression, anxiety, stroke and ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

People with Down syndrome face a much higher risk of developing ... the extra copy of chromosome 21 drives the overproduction of amyloid precursor protein. This excess production leads to the ...